Lenalidomide in Combination With Dexamethasone in Newly Diagnosed Multiple Myeloma - The ASCO Post
Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial - The Lancet Haematology
Tailored lenalidomide regimen benefits older patients with multiple myeloma
A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. - Abstract - Europe PMC
POMALYST® (pomalidomide) Treatment Option
MAIA Study | Int'l Myeloma Foundation
No Survival Benefit With All-Oral Regimen for Relapsed/Refractory Myeloma | MedPage Today
Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement | Leukemia
![PDF] A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/c492928e3f0ff31a9045ef665d1d8113a4831731/3-Figure1-1.png "PDF] A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma | Semantic Scholar")
PDF] A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma | Semantic Scholar
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial - The Lancet Oncology
Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial -
VisualAbstract Panobinostat, lenalidomide, bortezomib, and dexamethasone was well-tolerated and showed potential in treating relapsed/refractory multiple myeloma | 2 Minute Medicine
Lenalidomide, Dexamethasone, and Carfilzomib for Newly Diagnosed Multiple Myeloma | Cancer Nursing Today
Recommendations for MM front-line therapy. ASCT = autologous stem cell... | Download Scientific Diagram
Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone in Myeloma
Adding elotuzumab to lenalidomide and dexamethasone does not improve PFS in patients with newly diagnosed multiple myeloma - BJH
Cancers | Free Full-Text | How to Manage Patients with Lenalidomide-Refractory Multiple Myeloma
Elotuzumab plus lenalidomide and dexamethasone for newly diagnosed multiple myeloma: a randomized, open-label, phase 2 study in Japan | SpringerLink
Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone - ScienceDirect
Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second‐line lenalidomide + dexamethasone induction in multiple myeloma - Lund - 2018 - Cancer Medicine - Wiley Online Library
VisualAbstract: Carfilzomib, dexamethasone, and lenalidomide superior to lenalidomide monotherapy for multiple myeloma | 2 Minute Medicine
Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma | NEJM
Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma - ScienceDirect
Lenalidomide with Low- or High-Dose Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma (MM) | Research To Practice
